Sepsis Strategies in Development

Clinics in Chest Medicine

Volumn 29, Issue 4, 2008, Pages 735-747

  LaRosa, Steven P ^a,b   Opal, Steven M ^a,c  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Anticoagulants; Complement; Cytokines; Endotoxin; Sepsis; Therapeutics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; 6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; ADENOSINE A2A RECEPTOR AGONIST; ALKALINE PHOSPHATASE; ANTITHROMBIN; ATL 313; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CURCUMIN; CYTOFAB; CYTOKINE; ENDOTOXIN; ERITORAN; INCYCLINIDE; INO 1001; LACTOFERRIN; LIPOPOLYSACCHARIDE VACCINE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; POLYMYXIN B; RECOMBINANT ALKALINE PHOSPHATASE; RECOMBINANT THROMBOMODULIN; ROSIGLITAZONE; STATIN; SUPERANTIGEN; SUPERANTIGEN ANTAGONIST; TALACTOFERRIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ULINASTATIN; UNCLASSIFIED DRUG; VACCINE;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC THERAPY; APHERESIS; CONTINUOUS INFUSION; DRUG RESEARCH; DRUG TARGETING; EXPERIMENTAL THERAPY; FLUID RESUSCITATION; HEMOFILTRATION; HUMAN; IMMUNOTHERAPY; INFECTION CONTROL; INFLAMMATION; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS;

ANTICOAGULANTS; COMBINED MODALITY THERAPY; CRITICAL CARE; CYTOKINES; ENDOTOXINS; HUMANS; MULTIPLE ORGAN FAILURE; PROTEIN C; RECOMBINANT PROTEINS; RESUSCITATION; SEPSIS; SUPERANTIGENS; SURVIVAL RATE;

EID: 54049158577     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2008.06.007     Document Type: Review

References (131)

1. Visintin A., Halmen K.A., Latz E., et al. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 175 10 (2005) 6465-6472
2. Kim H.M., Park B.S., Kim J.-I., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 130 (2007) 906-917
3. Solomon S.B., Cui X., Gerstenberger E., et al. Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis 193 5 (2006) 634-644
4. Lynn M., Rossignol D.P., Wheeler J.L., et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 187 4 (2003) 631-639
5. Bennett-Guerrero E., Grocott H.P., Levy J.H., et al. A phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 104 2 (2007) 378-383
6. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol 64 1 (1998) 14-18
7. Heyderman R.S., Ison C.A., Peakman M., et al. Neutrophil response to Neisseria meningitidis: inhibition of adhesion molecule expression and phagocytosis by recombinant bactericidal/permeability-increasing protein (rBPI21). J Infect Dis 179 5 (1999) 1288-1292
8. Jellema W.T., Veerman D.P., DeWinter R.J., et al. In vivo interaction of endotoxin and recombinant bactericidal/permeability-increasing protein (rBPI23): hemodynamic effects in a human endotoxemia model. J Lab Clin Med 140 4 (2002) 228-235
9. Schultz H., Weiss J., Carroll S.F., et al. The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies. J Leukoc Biol 69 4 (2001) 505-512
10. Levin M., Quint P.A., Goldstein B., et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomized trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356 9234 (2000) 961-967
11. Giroir B.P., Scannon P.J., and Levin M. Bactericidal/permeability-increasing protein-lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia. Crit Care Med 29 7Suppl (2001) S130-S135
12. Japelj B., Pristovsek P., Majerle A., et al. Structural origin of endotoxin neutralization and antimicrobial activity of a lactoferrin-based peptide. J Biol Chem 280 17 (2005) 16955-16961
13. Andrä J., Gutsmann T., Garidel P., et al. Mechanisms of endotoxin neutralization by synthetic cationic compounds. J Endotoxin Res 12 5 (2006) 261-277
14. Ellison III R.T. The effects of lactoferrin on gram-negative bacteria. In: Hutchens T.W., Rumball S.V., and Lönnerdal B. (Eds). Lactoferrin: structure and function (1994), Plenum Press, New York 71-90
15. Zimecki M., Artym J., Chodaczek G., et al. Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm Res 53 7 (2004) 292-296
16. Andersen J.H. Technology evaluation: rh lactoferrin, Agennix. Curr Opin Mol Ther 6 (2004) 344-349
17. Bentala H., Verweij W.R., Huizinga-Van der Vlag A., et al. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 18 6 (2002) 561-566
18. Verweij W.R., Bentala H., Guizinga-Van der Vlag A., et al. Protection against an Escherichia coli-induced sepsis by alkaline phosphatase in mice. Shock 22 2 (2004) 174-179
19. van Veen S.Q., van Vliet A.K., Wulferink M., et al. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun 73 7 (2005) 4309-4314
20. Su F., Brands R., Wang Z., et al. Beneficial effects of alkaline phosphatase in septic shock. Crit Care Med 34 8 (2006) 2182-2187
21. Yamada M., Ichikawa T., Li M., et al. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate. J Med Chem 48 23 (2005) 7457-7467
22. Land W.G. Innate immunity-mediated allograft rejection and strategies to prevent it. Transplant Proc 39 3 (2007) 667-672
23. Bernard GR, Wheeler AP, Rice TW, et al. TAK-242 treatment for severe sepsis: a randomized controlled trial [abstract 264]. In: editors. Programs and Abstracts for the Society for Critical Care Medicine Meeting. Honolulu (HI): 2008. p. 946.
24. Kushi H., Miki T., Nakahara J., et al. Hemoperfusion with an immobilized Polymyxin B fiber column improves tissue oxygen metabolism. Ther Apher Dial 10 5 (2006) 430-435
25. Uriu K., Osajima A., Hiroshige K., et al. Endotoxin removal by direct hemoperfusion with an adsorbent column using Polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock. Am J Kidney Dis 39 5 (2002) 937-947
26. Kushi H., Miki T., Okamaoto K., et al. Early hemoperfusion with an immobilized Polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 9 6 (2005) R653-R661
27. Sakamoto Y., Mashiko K., Matsumoto H., et al. Relationship between effect of Polymyxin B-immobilized fiber and high-mobility group box-1 protein in septic shock patients. ASAIO J 53 3 (2007) 324-328
28. Cruz D.N., Bellomo R., and Ronco C. Clinical effects of Polymyxin B-immobilized fiber column in septic patients. Contrib Nephrol 156 (2007) 444-451
29. Ronco C. The place of early haemoperfusion with Polymyxin B fibre column in the treatment of sepsis. Crit Care 9 6 (2005) 631-633
30. Eisenhauer T., Armstrong V.W., Wieland H., et al. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 65 (1987) 161-168
31. Samtleben W., Bengsch S., Boos K.S., et al. HELP apheresis in the treatment of sepsis. Artif Organs 22 (1998) 43-46
32. Bengsch S., Boos K.S., Nagel D., et al. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 23 (2005) 494-500
33. Opal S.M., Palardy J.E., Chen W., et al. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms. J Infect Dis 192 (2005) 2074-2080
34. Cross A.S., Opal S.M., Palardy J.E., et al. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/ group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21 (2003) 4576-4587
35. Opal S.M. The host response to endotoxin, anti-LPS strategies and the management of severe sepsis. Int J Med Microbiol 297 (2007) 365-377
36. Visvanathan K., Charles A., Bannan J., et al. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun 69 2 (2001) 875-884
37. Hong-Geller E., and Gupta G. Therapeutic approaches to superantigen-based diseases: a review. J Mol Recognit 16 2 (2003) 91-101
38. Miwa K., Fukuyama M., Matsuno N., et al. Physiological response to superantigen-adsorbing hemoperfusion in toxin-concentration-controlled septic swine. Blood Purif 24 3 (2006) 319-326
39. Hong-Geller E., Möllhoff M., Shiflett P.R., et al. Design of chimeric receptor mimics with different TcR Vbeta isoforms. Type-specific inhibition of superantigen pathogenesis. J Biol Chem 279 7 (2004) 5676-5684
40. Honoré P.M., Joannes-Boyau O., and Gressens B. Blood and plasma treatments: the rationale of high-volume hemofiltration. Contrib Nephrol 156 (2007) 387-395
41. Honoré P.M., and Joannes-Boyau O. High volume hemofiltration (HVHF) in sepsis: a comprehensive review of rationale, clinical applicability, potential indications and recommendations for future research. Int J Artif Organs 27 12 (2004) 1077-1082
42. Joannes-Boyau O., Rapaport S., Bazin R., et al. Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock. ASAIO J 50 1 (2004) 102-109
43. Ronco C., Bellomo R., Homel P., et al. Effects of different doses of continuous veno-venous haemofiltration. Lancet 356 (2000) 26-30
44. Cornejo R., Downey P., Castro R., et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 32 5 (2006) 713-722
45. Humes H.D., MacKay S.M., Funke A.J., et al. Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int 55 6 (1999) 2502-2514
46. Issa N., Messer J., and Paganini E.P. Renal assist device and treatment of sepsis-induced acute kidney injury in intensive care units. Contrib Nephrol 156 (2007) 419-427
47. Tumlin J, Wali R, Brennan K, et al. Effect of the renal assist device (RAD) on mortality of dialysis-dependent acute renal failure: a randomized, open-labeled, multicenter, phase II trial [abstract]. Presented at the American Society of Nephrology (ASN) 38th Annual Meeting. Philadelphia, February 2-6, 2008.
48. Humes H.D., Weitzel W.F., Bartlett R.H., et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 66 (2004) 1578-1588
49. Rice T.W., Wheeler A.P., Morris P.E., et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine Fab for injection (CytoFab) in severe sepsis. Crit Care Med 34 (2006) 2271-2281
50. Borovikova L.V., Ivanova S., Zhang M., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000) 458-462
51. van Westerloo D.J., Giebelen I.A., Meijers J.C., et al. Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. J Thromb Haemost 4 (2006) 1997-2002
52. van Westerloo D.J., Giebelen I.A., Florquin S., et al. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 191 (2005) 2138-2148
53. Wang H., Liao H., Ochani M., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10 (2004) 1216-1221
54. Pavlov V.A., Ochani M., Yang L.H., et al. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 35 (2007) 1139-1144
55. Mantell L.L., Parrish W.R., and Ulloa L. HMGB-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25 (2006) 4-11
56. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-252
57. Sunden-Cullberg J., Norrby-Teglund A., Rouhiainen A., et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33 (2005) 564-573
58. Yang H., Ochani M., Li J., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101 (2004) 296-301
59. Li J., Kokkola R., Tabibzadeh S., et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9 (2003) 37-45
60. Huston J.M., Gallowitsch-Puerta M., Ochani M., et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med 35 (2007) 2762-2768
61. Chen X., Li W., and Wang H. More tea for septic patients?-Green tea may reduce endotoxin-induced release of high mobility group box 1 and other pro-inflammatory cytokines. Med Hypotheses 66 (2006) 660-663
62. Chen G., Li J., Qiang X., et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 46 (2005) 623-627
63. Schmidt A.M., Yan S.D., Yan S.F., et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108 (2001) 949-955
64. Chavakis T., Bierhas A., Al-Fakhri N., et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198 (2003) 1507-1515
65. Liliensiek B., Weigand M.A., Beirhaus A., et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113 (2004) 1641-1650
66. Lutterloh E., Opal S.M., Pittman D., et al. Inhibition of receptor for advanced glycation endproducts as a novel treatment strategy in severe sepsis. Crit Care 11 6 (2007) 122-130
67. Grutkoski P.S., Chen Y., Chung C.S., et al. Sepsis-induced SOCS-3 expression is immunologically restricted to phagocytes. J Leukoc Biol 74 5 (2003) 916-922
68. Chung C.S., Chen Y., Grutkoski P.S., et al. SOCS-1 is a central mediator of steroid-increased thymocyte apoptosis and decreased survival following sepsis. Apoptosis 12 7 (2007) 1143-1153
69. Watanabe H., Kubo M., Numata K., et al. Overexpression of suppressor of cytokine signaling-5 in T cells augments innate immunity during septic peritonitis. J Immunol 177 112 (2006) 8650-8657
70. Sullivan G.W., Rieger J.M., Scheld W.M., et al. Cyclic AMP -dependent inhibition of human neutrophil oxidative activity by substituted 2-propynlcyclohexyl adenosine A (2A) receptor agonists. Br J Pharmacol 132 (2001) 1017-1026
71. Eigler A., Greten T.F., Sinha B., et al. Endogenous adenosine curtails lipopolysaccharide-stimulated tumor necrosis factor synthesis. Scand J Immunol 45 (1997) 132-139
72. Hourani S.M. Purinoreceptors and platelet aggregation. J Auton Pharmacol 16 (1996) 349-352
73. Sullivan G.W., Fang G., Linden J., et al. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis 189 (2004) 1897-1904
74. Cavalcante I.C., Castro M.V., Barreto A.R.F., et al. Effect of novel A2A adenosine receptor agonist ATL313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun 74 5 (2006) 2602-2612
75. Zingarelli B., and Cook J.A. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23 (2005) 393-399
76. Collin M., Murch O., and Thiemermann C. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Crit Care Med 34 (2006) 1131-1138
77. Cuzzocrea S., Pisano B., Dugo L., et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 32 (2004) 457-466
78. Siddiqui A.M., Cui X., Wu R., et al. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Crit Care Med 34 (2006) 1874-1882
79. Solorzano C.C., Ksontini R., Pruitt J.H., et al. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock 7 (1997) 427-431
80. D'Agostino P., Ferlazzo V., Milano S., et al. Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line. Int Immunopharmacol 1 (2001) 1765-1776
81. Maitra S.R., Bhaduri S., Chen E., et al. Role of chemically modified tetracycline on TNF-alpha and mitogen-activated protein kinases in sepsis. Shock 22 (2004) 478-481
82. Steinberg J., Halter J., Schiller H., et al. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock 24 (2005) 348-356
83. Halter J.M., Pavone L.A., Steinberg J.M., et al. Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture. Shock 26 (2006) 587-591
84. Diomede L., Albani D., Sottocorno M., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21 (2001) 1327-1332
85. Liappis A.P., Kan V.L., Rochester C.G., et al. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33 (2001) 1352-1357
86. Almog Y., Shefer A., Novack V., et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110 (2004) 880-885
87. Merx M.W., Liehn E.A., Graf J., et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112 (2005) 117-124
88. Steiner S., Speidl W.S., Pleiner J., et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111 (2005) 1841-1846
89. Niessner A., Steiner S., Speidl W.S., et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 189 (2006) 408-413
90. Creasey A. New potential therapeutic modalities: tissue factor pathway inhibitor. Sepsis 3 (1999) 173-182
91. Rhewald M., and Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A 98 14 (2001) 7742-7747
92. Senden N.H.M., Jeunhomme T.M.A.A., Heemserk J.W.M., et al. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 161 (1998) 4318-4324
93. Schaeffer P., Mares A.M., Dol F., et al. Coagulation factor Xa induces endothelium-dependent relaxation in rat aorta. Circ Res 81 (1997) 824-828
94. Park C.T., Creasey A.A., and Wright S.D. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 89 2 (1997) 4268-4274
95. Abraham E., Reinhart K., Opal S., et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. JAMA 290 (2003) 238-247
96. Opal S, Wunderink R, Laterre PF, et al. Therapeutic rationale for tissue factor pathway inhibitor for severe community-acquired pneumonia (CAP) [abstract 234]. In: editors. Final program and abstracts of the 42nd annual meeting Infectious Disease Society of America. Boston: 2004. p. 76.
97. LaRosa S.P., Opal S.M., Utterback B., et al. Decreased protein C, protein S, and antithrombin III levels are predictive of poor outcome in gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 10 1 (2006) 25-31
98. Warren B.L., Eid A., Singer P., et al. High-dose antithrombin III in severe sepsis (the KyberSept trial). JAMA 286 (2001) 1869-1887
99. Weidermann C.J., Hoffman J.N., Juers M., et al. High dose antithrombin III in the treatment of severe sepsis with high risk of death. Crit Care Med 34 2 (2006) 285-292
100. Levy J.H., Despotis G.J., Szlam F., et al. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 96 5 (2002) 1095-1102
101. Mohri M., Sugimoto E., Sata M., et al. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation-a comparison with other anticoagulants. Thromb Haemost 82 (1999) 1687-1693
102. Uchiba M., Okajima K., Murakami K., et al. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost 74 (1995) 1265-1270
103. Abeyama K., Stern D.M., Ito Y., et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115 (2005) 1267-1274
104. Van de W.M., Plaisance S., De V.A., et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 4 (2006) 1813-1824
105. Nakashima M., Kanamura M., Umemura K., et al. Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers. J Clin Pharmacol 38 (1998) 40-44
106. Mohri M., Gonda Y., Oka M., et al. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fibrinolysis 8 (1997) 274-283
107. Saito H., Maruyama I., Shimazaki S., et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 (2007) 31-41
108. Haeney M.R. The role of the complement cascade in sepsis. J Antimicrob Chemother 41 Suppl A (1998) 41-46
109. Guo R.F., Riedemann N.C., and Ward P.A. Role of C5a-C5aR interaction in sepsis. Shock 21 1 (2004) 1-7
110. Czermak B.J., Sarma V., Pierson C.L., et al. Protective effects of C5a blockade in sepsis. Nat Med 5 (1999) 788-792
111. Laudes I.J., Chu J.C., Sikranth S., et al. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 160 (2002) 1867-1875
112. Hotchkiss R.S., Swanson P.E., Freeman B.D., et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27 (1999) 1230-1251
113. Hotchkiss R.S., Tinsley K.W., Swanson P.E., et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166 (2001) 6952-6963
114. Oberholzer C., Oberholzer A., Clare-Salzler M., et al. Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J 15 (2001) 879-892
115. Hotchkiss R.S., Chang K.C., Swanson P.E., et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 1 (2000) 496-501
116. Hotchkiss R.S., Tinsley K.W., Swanson P.E., et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A 96 (1999) 14541-14546
117. Chung C.S., Song G.Y., Lomas J., et al. Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity. J Leukoc Biol 74 (2003) 344-351
118. Weaver J.G., Rouse M.S., Steckelberg J.M., et al. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J 18 (2004) 1185-1191
119. Fink M.P. Bench-to-bedside review: cytopathic hypoxia. Crit Care 6 (2002) 491-499
120. Oliver F.J., Menissier-De Murcia J., Nacci C., et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 18 (1999) 4446-4454
121. Goldfarb R.D., Marton A., Szabo E., et al. Protective effect of a novel, potent inhibitor of poly(adenosine 5'-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med 30 (2002) 974-980
122. Murakami K., Enkhbaatar P., Shimoda K., et al. Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock 21 (2004) 126-133
123. Opal S.M., Lim Y.-P., E Siryaporn E., et al. Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: a potential clinical marker and mediator of severe sepsis. Crit Care Med 35 (2007) 387-392
124. Garantziotis S., Hillingworth J.W., Ghanayem R.B., et al. Inter-α-trypsin inhibitor attenuates complement activation and complement-induced lung injury. J Immunol 179 (2007) 4187-4192
125. Zhongguo W.E., Zhong Bing J., Jue Y., et al. Clinical study on effects of ulinastatin on patients with systemic inflammatory response syndrome. Chinese Crit Care Med 17 4 (2005) 228-230
126. Lin H.Y. Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin. Zhonghua Yi Xue Za Zhi 87 7 (2007) 451-457
127. Harris H.A., Katzenellenbogen J.A., and Katzenellenbogen B.S. Characterization of the biological roles of the estrogen receptors, ER alpha and ER beta, in estrogen target tissues in vivo through the use of an ER alpha-selective ligand. Endocrinology 143 (2002) 4172-4177
128. Deshpande R., Khalili H., Pergolizzi R.G., et al. Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages. Am J Reprod Immunol 38 (1997) 46-54
129. Kuebler J.F., Jarrar D., Toth B., et al. Estradiol administration improves splanchnic perfusion following trauma-hemorrhage and sepsis. Arch Surg 137 (2002) 74-79
130. Opal S.M., Keith J., Cristofaro P., et al. The activity of estrogen receptor pathway selective ligands in experimental models of sepsis and inflammation. Shock 24 6 (2005) 535-540
131. Cristofaro P., Opal S.M., Keith J., et al. WAY202196, a selective estrogen receptor beta agonist, protects against death in experimental septic shock. Crit Care Med 34 6 (2006) 2188-2193